Talaris Therapeutics (Talaris Therapeutics) EPS (Basic) : $-1.79 (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Talaris Therapeutics EPS (Basic)?

Talaris Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Jun. 2023 was $-0.35. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.79.

Talaris Therapeutics's EPS (Diluted) for the three months ended in Jun. 2023 was $-0.35. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.79.

Talaris Therapeutics's EPS without NRI for the three months ended in Jun. 2023 was $-0.20. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was -1.53.

During the past 3 years, the average EPS without NRI Growth Rate was -27.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Talaris Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -27.80% per year. The lowest was -27.80% per year. And the median was -27.80% per year.

Talaris Therapeutics EPS (Basic) Historical Data

The historical data trend for Talaris Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talaris Therapeutics EPS (Basic) Chart

Talaris Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

EPS (Basic)

-0.86

-1.07

-1.64

-1.79

Talaris Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EPS (Basic)	Get a 7-Day Free Trial										-0.44	-0.46	-0.44	-0.54	-0.35

Talaris Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Talaris Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-73.894	-	0)	/	41.248
	=	-1.79

Talaris Therapeutics's Basic EPS for the quarter that ended in Jun. 2023 is calculated as

Basic EPS (Q: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-14.738	-	0)	/	42.172
	=	-0.35

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.79

Talaris Therapeutics (NAS:TALS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Talaris Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Talaris Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Talaris Therapeutics (Talaris Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Talaris Therapeutics Inc (NAS:TALS) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

93 Worcester Street, Wellesley, MA, USA, 02481

Website

https://www.talaristx.com

Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.

Executives

Cariad Chester	director	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Yung H. Chyung	officer: Chief Medical Officer	C/O SCHOLAR ROCK, 620 MEMORIAL DR., 2ND FLOOR, CAMBRIDGE MA 02139
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
W Bradford Middlekauff	officer: CBO, GC and Secretary	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Aaron Kantoff	director	C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH
Sandeep Chidambar Kulkarni	director, officer: CEO	92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Kevin Bruce Johnson	officer: Chief Regulatory Officer	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Ryan F. Robinson	officer: Interim CFO	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Parvinder Thiara	director	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Susan Dana Jones	officer: Chief Technology Officer	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Suzanne Ildstad	director, 10 percent owner, officer: Chief Scientific Officer	C/O TALARIS THERAPEUTICS, INC., 93 WORCESTER STREET, SUITE 120, WELLESLEY MA 02481
Scott Requadt	director, officer: See Remarks	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025